Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KY1044 |
| Synonyms | |
| Therapy Description |
KY1044 is a monoclonal antibody that targets ICOS (CD278), which has potential anti-tumor activity (Cancer Res 2018;78(13 Suppl):Abstract nr 2792). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KY1044 | KY-1044|KY 1044 | ICOS Antibody 6 | KY1044 is a monoclonal antibody that targets ICOS (CD278), which has potential anti-tumor activity (Cancer Res 2018;78(13 Suppl):Abstract nr 2792). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Terminated | USA | POL | ITA | HUN | GBR | 1 |